Navigation Links
Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology

Neurological disability typically accumulates over time and includes muscle weakness and spasticity, balance and coordination problems, as well as memory impairment and depression. Other symptoms include numbness, pain, slurred speech and blurred vision. Many patients experience fatigue and problems with bladder, bowel or sexual function.

While MS has traditionally been considered a T-cell mediated disease, recent research suggests that B-cells may play multiple roles in the initiation and development of MS.

Rituxan Safety Profile in Rheumatoid Arthritis and Oncology
The safety profile of Rituxan in rheumatoid arthritis and non-Hodgkin's lymphoma (NHL) has been evaluated through a number of clinical trials.

The most common adverse events observed in rheumatoid arthritis (RA) patients treated with Rituxan in clinical studies of up to 24 weeks were infection and infusion reactions. Among non-Hodgkin's lymphoma patients treated with Rituxan in clinical studies, the most common adverse events were infusion reactions and cytopenias (low blood cell counts).

The majority of patients experiencing an infusion-related reaction do so during their first Rituxan infusion. These symptoms include but are not limited to: flu-like illness, fever, chills/rigors, nausea, urticaria, headache, bronchospasm, angioedema, hypotension and hypoxia. These symptoms vary in severity and generally are reversible.

Severe infusion reactions have been reported in patients treated with Rituxan, some with fatal outcomes. These severe reactions typically occur during the first infusion. The most severe manifestations and sequelae include hypoxia, pulmonary infiltrates, acute respiratory distress syndrome, myocardial infarction, ventricular fibrillation and cardiogenic shock.

Acute renal failure requiring dialysis with instances of fatal outcome has been reported in the setting of tumor lysis syndrome following treatment with Rituxan in patients wi
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple Sclerosis Presented at the American Academy of Neurology
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:5/27/2015)...  Cambrex Corporation (NYSE: CBM, "Cambrex") is pleased to announce ... Financial Officer, will present at the Jefferies 2015 Global Healthcare ... New York City . The ... the Cambrex website at www.cambrex.com in the Investors ... available for 90 days after the live event concludes.  ...
(Date:5/27/2015)... , May 27, 2015  Novartis will ... in 21 medicines and 11 investigational compounds across ... American Society of Clinical Oncology (ASCO) Annual Meeting, ... European Hematology Association (EHA), June 11-14. Data will ... cancer types, including melanoma, lung, breast, kidney and ...
(Date:5/27/2015)... , May 25, 2015 Research and Markets ... of the "Research and Future Development Trend Forecast ... offering. At present, there are 35,600 dialysis ... concentration ratio are large due to the different regional ... dialysis centers in other Asian countries are operated by ...
Breaking Medicine Technology:Novartis presents new data on 21 medicines and 11 investigational compounds at ASCO and EHA 2Novartis presents new data on 21 medicines and 11 investigational compounds at ASCO and EHA 3Novartis presents new data on 21 medicines and 11 investigational compounds at ASCO and EHA 4Novartis presents new data on 21 medicines and 11 investigational compounds at ASCO and EHA 5Novartis presents new data on 21 medicines and 11 investigational compounds at ASCO and EHA 6Novartis presents new data on 21 medicines and 11 investigational compounds at ASCO and EHA 7Novartis presents new data on 21 medicines and 11 investigational compounds at ASCO and EHA 8China Dialysis Market Report: Research and Future Development Trends and Forecasts 2015-2020 2
(Date:5/27/2015)... (PRWEB) May 27, 2015 Genius Monkey ... their advanced programmatic marketing technology, they have boosted sales ... support on a regional level for seven Utah-based dealers. ... was through television and radio media. In 2014 the ... the help of Genius Monkey , shifted their ...
(Date:5/27/2015)... CA (PRWEB) May 27, 2015 With ... total communication environment where the message is not only heard ... toy, drawing, or virtually any motivating image. This award-winning and ... to offer. , Now, using InnerVoice Sender app ... can be sent to a learner remotely for no additional ...
(Date:5/27/2015)... Iowa (PRWEB) May 27, 2015 With ... away, a poll conducted during the "ACA - Controlling ... poll participants, 75% are currently in the process of ... over 15% were confidently prepared for the reporting mandates. ... shown during the webinar, those who are currently vetting ...
(Date:5/27/2015)... http://www.smarterskindermatology.com , is taking skin care customization to a ... for patients to find skin care products that work specifically ... a cosmetic dermatologist based in New York and is the ... DNA test uses 16 genetic markers to evaluate the following ... Firmness and elasticity , 2. Glycation , 3. Sun damage ...
(Date:5/27/2015)... Oregon (PRWEB) May 27, 2015 ... in North America, is offering free design advice to ... outside environment. , “Light pollution caused by streetlights, ... cause a restless night’s sleep, said Kim Rush, VP ... of numerous cities across North America with recently installed ...
Breaking Medicine News(10 mins):Health News:Genius Monkey Boosts Utah Honda Dealers Website Traffic 142% 2Health News:Newly Released: InnerVoice Sender App Ups the Ante in Communication Technology for Autism with Remote Prompting 2Health News:Newly Released: InnerVoice Sender App Ups the Ante in Communication Technology for Autism with Remote Prompting 3Health News:Newly Released: InnerVoice Sender App Ups the Ante in Communication Technology for Autism with Remote Prompting 4Health News:Employers are On Track for ACA Reporting According to Businessolver Poll 2Health News:SmarterSkin Dermatology is Now Offering Skin DNA Analysis 2Health News:Decorview Helps Homeowners Combat Light Pollution 2
... the possibility of building the labs across the world to ... invest $1.9bn from various developed countries where the investigation with ... Blair while facing questions in the House of Commons about ... that precautions were adequate. He proposed to set up labs ...
... new cases of bird flu in a dead mallard and a ... two dead swans// in southern Hungary. ,Previously the government ... outside Budapest. ,The mallard was found in Szentendre, a ... 30 kilometers south of the capital. ,One of the ...
... Gujarat Wednesday lifted its ban on sales of poultry products ... in the region.,According to officials, the ban was lifted from ... of Uchchhal taluka, where bird flu was detected a week ... is adjacent to Maharashtra's Nandurbar district that last month reported ...
... research has showed that even though it is 60 years ... Nagasaki in Japan, survivors are still facing the effects of ... continue to develop thyroid nodules, sometime benign and at other ... to radiation. It has also been observed that the younger ...
... wrongly charged for free services such as making a cup ... Age Concern Scotland//. Legally, such food preparation techniques that fall ... ,The thirteen councils that have been blamed for ... Executive, in an attempt to resolve the issue. A similar ...
... has now established that a delayed-release stimulant, used for ... with less abuse, when compared to other stimulant drugs//. ... an oral formulation have not been reported to produce ... results of the study can be found in the ...
Cached Medicine News:Health News:Concerta, Drug Used in ADHD Treatment Less Likely To Result In Abuse 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: